ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023
/PRNewswire/ -- ImmVira submitted four abstracts covering latest results from Phase I/II clinical trials of MVR-T3011 IT (intratumoral injection) and MVR-T3011...
Source: prnewswire.com